The use of TNF-alpha blocking agents in rheumatoid arthritis: an update.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 17714062
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adalimumab-associated multiple sclerosis.

  2007cited by this paper
• The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

  2006cited by this paper
• Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis.

  2006cited by this paper
• Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register.

  2006cited by this paper
• Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis.

  2006cited by this paper
• Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

  2006cited by this paper
• Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

  2006cited by this paper
• Neurological complications of infliximab.

  2006cited by this paper
• Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study

  2006cited by this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006

  2006cited by this paper
• Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again).

  2006cited by this paper
• Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.

  2006cited by this paper
• Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression.

  2006cited by this paper
• Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison

  2006cited by this paper
• Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance.

  2006cited by this paper
• Shortening infusion times for infliximab administration.

  2006cited by this paper
• Nonresponse to tumor necrosis factor antagonists—is there any point in re-treatment?

  2006cited by this paper
• Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice.

  2006cited by this paper
• The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.

  2005cited by this paper
• Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

  2005cited by this paper
• Infliximab for the treatment of early rheumatoid arthritis

  2005cited by this paper
• Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.

  2005cited by this paper
• Infections associated with tumor necrosis factor-alpha antagonists.

  2005cited by this paper
• Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis.

  2005cited by this paper
• Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

  2005cited by this paper
• Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

  2005cited by this paper
• Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.

  2005cited by this paper
• Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.

  2005cited by this paper
• Bacillus calmette-guérin vaccination in a patient treated with infliximab.

  2005cited by this paper
• Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-contro

  2005cited by this paper
• Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.

  2005cited by this paper
• CDP-870 (certolizumab) in rheumatoid arthritis

  2005cited by this paper
• Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab

  2004cited by this paper
• Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection

  2004cited by this paper
• Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid Arthritis

  2004cited by this paper
• Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

  2004cited by this paper
• Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

  2004cited by this paper
• The use of TNF-α blocking agents in rheumatoid arthritis: an overview

  2004cited by this paper
• Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

  2004cited by this paper
• Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.

  2004cited by this paper
• Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.

  2004cited by this paper
• Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

  2004cited by this paper
• Is there a rationale for switching from one anti-tumor necrosis factor agent to another?

  2004cited by this paper
• Anti-TNF-alpha-induced systemic lupus syndrome.

  2003cited by this paper
• Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

  2003cited by this paper
• Infections and anti-tumor necrosis factor alpha therapy.

  2003cited by this paper
• Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease.

  2003cited by this paper
• Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

  2003cited by this paper
• The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis.

  2003cited by this paper
• Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial

  2003cited by this paper
• Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist

  2003cited by this paper
• Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy.

  2003cited by this paper
• Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

  2003cited by this paper
• Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.

  2003cited by this paper
• Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.

  2003cited by this paper
• The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study.

  2003cited by this paper
• CDP-870. Celltech/Pfizer.

  2003cited by this paper
• PEG-sTNF-RI. Amgen.

  2003cited by this paper
• Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis.

  2003cited by this paper
• Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.

  2003cited by this paper
• Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.

  2002cited by this paper
• Recommendations for the prevention and management of tuberculosis in patients taking infliximab.

  2002cited by this paper
• Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.

  2002cited by this paper
• Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.

  2002cited by this paper
• Drug-induced systemic lupus erythematosus associated with etanercept therapy.

  2002cited by this paper
• Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.

  2002cited by this paper
• Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies.

  2002cited by this paper
• What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.

  2002cited by this paper
• Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation

  2002cited by this paper
• The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.

  2002cited by this paper
• Links between radiological change, disability, and pathology in rheumatoid arthritis.

  2001cited by this paper
• Cytokine pathways and joint inflammation in rheumatoid arthritis.

  2001cited by this paper
• Effects of Tumor Necrosis Factor Alpha on Host Immune Response in Chronic Persistent Tuberculosis: Possible Role for Limiting Pathology

  2001cited by this paper
• Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

  2001cited by this paper
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

  2001cited by this paper
• Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

  2001cited by this paper
• A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

  2000cited by this paper
• Etanercept (Enbrel): update on therapeutic use

  2000cited by this paper
• Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.

  2000cited by this paper
• Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.

  2000cited by this paper
• Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody.

  2000cited by this paper
• Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

  2000cited by this paper
• Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis*

  2000cited by this paper
• Infliximab: a review of its use in the management of rheumatoid arthritis.

  2000cited by this paper
• Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

  1999cited by this paper
• Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis

  1999cited by this paper
• On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease

  1999cited by this paper
• A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

  1999cited by this paper
• Etanercept: therapeutic use in patients with rheumatoid arthritis

  1999cited by this paper
• Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7

  1999cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

  1999cited by this paper
• Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

  1998cited by this paper
• Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

  1997cited by this paper
• Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.

  1996cited by this paper
• Role of cytokines in rheumatoid arthritis.

  1996cited by this paper
• Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease

  1995cited by this paper
• Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis.

  1995cited by this paper
• Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

  1995cited by this paper
• American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

  1995cited by this paper
• Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

  1994cited by this paper

• Cationic pH-sensitive liposome-based subunit tuberculosis vaccine induces protection in mice challenged with Mycobacterium tuberculosis.

  2024cites this paper
• Hybrids of aurantiamide acetate and isopropylated genipin as potential anti‐inflammatory agents: The design, synthesis, and biological evaluation

  2020cites this paper
• Down-regulation of microRNA-142-3p inhibits the aggressive phenotypes of rheumatoid arthritis fibroblast-like synoviocytes through inhibiting nuclear factor-κB signaling

  2019cites this paper
• Hematopoietic prostaglandin D synthase–derived prostaglandin D2 ameliorates adjuvant‐induced joint inflammation in mice

  2019cites this paper
• Proinflammatory Differentiation of Macrophages Through Microparticles That Form Immune Complexes Leads to T- and B-Cell Activation in Systemic Autoimmune Diseases

  2019cites this paper
• An anti-inflammatory molecular mechanism of action of α-mangostin, the major xanthone from the pericarp of Garcinia mangostana: an in silico, in vitro and in vivo approach.

  2018cites this paper
• Association of different immunosuppressive medications with periodontal condition in patients with rheumatoid arthritis: Results from a cross-sectional study.

  2018cites this paper
• Extracellular vesicles are associated with the systemic inflammation of patients with seropositive rheumatoid arthritis

  2018cites this paper
• Anti-tumor necrosis factor-α therapy increases plaque burden in a mouse model of experimental atherosclerosis.

  2018cites this paper
• Marginal zone lymphoma: Associated autoimmunity and auto-immune disorders.

  2017cites this paper
• Extracellular Vesicles as Drug Delivery Vehicles for Rheumatoid Arthritis.

  2016cites this paper
• Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion

  2016cites this paper
• Drug outcome survey to evaluate anti-TNF treatment in rheumatoid arthritis: an Italian observational study (the DOSE study).

  2015cites this paper
• Understanding the major risk factors in the beginning and the progression of rheumatoid arthritis: current scenario and future prospects

  2015cites this paper
• Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL

  2015cites this paper
• Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

  2014cites this paper
• TL1A increased the differentiation of peripheral Th17 in rheumatoid arthritis.

  2014cites this paper
• ADAM-10 is overexpressed in rheumatoid arthritis synovial tissue and mediates angiogenesis.

  2013cites this paper
• The effect of targeted rheumatoid arthritis therapies on anti‐citrullinated protein autoantibody levels and B cell responses

  2013cites this paper
• Periodontal condition of patients with autoimmune diseases and the effect of anti-tumor necrosis factor-α therapy.

  2013cites this paper
• Defining the Role of GGTase-I in the Development of Rheumatoid Arthritis and Atherosclerosis

  2012cites this paper
• Biologic Rheumatoid Arthritis Therapies

  2012cites this paper
• Biologic Rheumatoid Arthritis Therapies

  2012cites this paper
• Cytokine Antagonists for the Treatment of Asthma

  2012cites this paper
• Longterm Retention of Tumor Necrosis Factor-α Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors

  2012cites this paper
• Endometriosis and autoimmune disease: association of susceptibility to moderate/severe endometriosis with CCL21 and HLA-DRB1.

  2011cites this paper
• [Treatment of persistent and difficult-to-control asthma: updating of anti IgE therapy].

  2011cites this paper
• Tratamiento del asma persistente y de difícil control: actualización de la terapia anti IgE

  2011cites this paper
• Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases

  2011cites this paper
• Biologics: a new weapon in the war against autoimmune joint disease

  2011cites this paper
• Interleukin-1 and tumor necrosis factor- α inhibit chondrogenesis by human mesenchymal stem cells through NF- κ B dependent pathways

  2011cites this paper
• Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

  2011cites this paper
• Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma

  2011cites this paper
• What causes Waldenström's macroglobulinemia: genetic or immune-related factors, or a combination?

  2011cites this paper
• Gene therapy in autoimmune diseases: challenges and opportunities.

  2010cites this paper
• Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis

  2010cites this paper
• A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis

  2010cites this paper
• Survival patterns in patients with Hodgkin's lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease.

  2010cites this paper
• Targeting the TNF-α pathway in sarcoidosis

  2010cites this paper
• Golimumab Therapy of Rheumatoid Arthritis: An Overview

  2010cites this paper
• [Tuberculosis in rheumatoid arthritis patients: the difficulty in making the diagnosis of latent infection].

  2010cites this paper
• Decoy receptor 3 is highly expressed in patients with rheumatoid arthritis

  2010cites this paper
• Interactions between octaarginine and U-937 human macrophages: global gene expression profiling, superoxide anion content, and cytokine production.

  2009cites this paper
• How safe are the biologicals in treating asthma and rhinitis?

  2009cites this paper
• Interleukin-1beta and tumor necrosis factor alpha inhibit chondrogenesis by human mesenchymal stem cells through NF-kappaB-dependent pathways.

  2009cites this paper
• Current Insights into the Pathogenesis of Graves’ Orbitopathy

  2009cites this paper
• Genetics- and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/ Waldenström's macroglobulinemia.

  2009cites this paper
• Atypical chemokine receptors in inflammatory disease.

  2009cites this paper
• Autoimmunity and lymphomagenesis

  2009cites this paper
• Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature.

  2009cites this paper
• Pharmacokinetic and Pharmacodynamic Modeling of a Humanized Anti-IL-13 Antibody in Naive and Ascaris-Challenged Cynomolgus Monkeys

  2009cites this paper
• Allergic bronchopulmonary aspergillosis after infliximab therapy for sarcoidosis: a potential mechanism related to T-helper cytokine balance.

  2009cites this paper
• What is the place of TNF in the pathogenesis of RA ?

  2009cites this paper
• Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors.

  2009cites this paper
• Genetic and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia

  2009cites this paper
• Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies

  2009cites this paper
• Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature

  2009cites this paper
• Biologikatherapie bei rheumatologischen Erkrankungen

  2008cites this paper
• Regulation of biomechanical signals by NF-κB transcription factors in chondrocytes

  2008cites this paper
• Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus

  2008cites this paper
• Tumor necrosis factor (TNF) blockers ignite FDA inquiry over cancer concerns.

  2008cites this paper
• Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis.

  2008cites this paper
• Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade

  2008cites this paper
• Anti-TNF-alpha therapies in chronic obstructive pulmonary diseases.

  2008cites this paper
• Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.

  2008cites this paper
• Re-activation of bovine tuberculosis in a patient treated with infliximab

  2008cites this paper
• [Effects of Tongbi Mixture 2 on expressions of CD28 and CD152 and content of tumor necrosis factor-alpha in peripheral blood in rats with collagen-induced arthritis].

  2008cites this paper
• Anti-TNF-α therapies in chronic obstructive pulmonary diseases

  2008cites this paper
• Anti-inflammatory Mechanism of Rungia pectinata (Linn.) Nees

  2008cites this paper
• [Biological therapy for the treatment of rheumatic diseases].

  2008cites this paper
• Expression, purification and structural analysis of human IL-18 binding protein: a potent therapeutic molecule for allergy.

  2008cites this paper
• Mesenchymal stem cells in arthritic diseases

  2008cites this paper
• Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models.

  2008cites this paper
• CD47-Fc fusion proteins as putative immunotherapeutic agents for the treatment of immunological and inflammatory diseases

  2008influential citation
• Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus.

  2008cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 277 Exploration of Conditions Affecting Cytokine Production in Experimental type 1 Diabetes Mellitus

  2007cites this paper
• Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Infliximab in the Treatment of Rheumatoid Arthritis

  year unknowncites this paper